Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Operating Expenses (2017 - 2025)

Puma Biotechnology's Operating Expenses history spans 9 years, with the latest figure at $58.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 27.64% year-over-year to $58.3 million; the TTM value through Dec 2025 reached $191.1 million, down 4.23%, while the annual FY2025 figure was $191.1 million, 4.23% down from the prior year.
  • Operating Expenses reached $58.3 million in Q4 2025 per PBYI's latest filing, up from $44.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $78.0 million in Q1 2021 to a low of $42.0 million in Q1 2025.
  • Average Operating Expenses over 5 years is $52.5 million, with a median of $48.9 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: crashed 40.42% in 2022, then grew 27.64% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $48.5 million in 2021, then grew by 14.7% to $55.7 million in 2022, then grew by 3.09% to $57.4 million in 2023, then decreased by 20.33% to $45.7 million in 2024, then rose by 27.64% to $58.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Operating Expenses are $58.3 million (Q4 2025), $44.9 million (Q3 2025), and $45.8 million (Q2 2025).